Sarcopenia Impact Among Older Patients With Newly Diagnosed Multiple Myeloma

Overview

About this study

The purpose of this study is to evaluate the association between baseline sarcopenia and high-grade chemotherapy toxicity during the first 4 cycles of treatment measured by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0, the Patient-Reported Outcomes (PRO) version of the CTCAE(PRO-CTCAE), and treatment discontinuation in older patients (≥60 years) with hematologic malignancies.

The hypothesis is that for older patients with hematologic malignanclies, sarcopenia is associated with higher likelihood of high-grade treatment-related chemotherapy toxicity and a higher rate of treatment discontinuation during the first 4 cycles of treatment.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥ 60 years.
  • Post-menopausal status - determined by self-reported last menstrual period ≥ 1 year ago, and/or history of hysterectomy +/- bilateral oophorectomy.
  • Diagnosis of Multiple Myeloma (MM) based on IMWG diagnostic criteria, leukemia (acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, chronic myelomonocytic leukemia) myelodysplastic syndrome, lymphoma (non-hodgkins lymphoma, hodgkins lymphoma).
  • Planned to start a new treatment within 30 days at Mayo Clinic in Rochester, MN. Patients who are receiving treatment at a location other than Mayo Clinic in Rochester, MN but undergoing evaluation prior to each cycle at Mayo Clinic in Rochester, MN.
  • Transplant eligible or ineligible.
  • Fluent in English (all assessment tools are in English).
  • Able to provide written informed consent.

Exclusion Criteria:

  • Not able to give informed consent.

Eligibility last updated 7/10/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Shaji Kumar, M.D.

Open for enrollment

Contact information:

Sarah Aug

(507) 538-1301

Aug.Sarah@mayo.edu

More information

Publications

Publications are currently not available